Scpharmaceuticals Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Scpharmaceuticals
SCPH Stock  USD 5.17  0.09  1.77%   
Scpharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Scpharmaceuticals' valuation are provided below:
Gross Profit
28.9 M
Profit Margin
(2.16)
Market Capitalization
272.9 M
Enterprise Value Revenue
6.3777
Revenue
42 M
We have found one hundred twenty available fundamental trend indicators for Scpharmaceuticals, which can be analyzed and compared to other ratios and to its competition. Traders should compare all of Scpharmaceuticals current fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 111.7 M. Enterprise Value is estimated to decrease to about 73 M

Scpharmaceuticals Total Revenue

38.15 Million

Check Scpharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scpharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 140.6 K, Interest Expense of 3.8 M or Selling General Administrative of 81.5 M, as well as many indicators such as Price To Sales Ratio of 4.12, Dividend Yield of 0.0 or PTB Ratio of 12.42. Scpharmaceuticals financial statements analysis is a perfect complement when working with Scpharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Scpharmaceuticals Stock
Check out the analysis of Scpharmaceuticals Correlation against competitors.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

Scpharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets93.4 M107.5 M59.5 M
Slightly volatile
Other Current Liabilities11 M10.4 M3.9 M
Slightly volatile
Total Current Liabilities9.1 M14.9 M6.3 M
Slightly volatile
Other Liabilities9.1 M8.7 M2.1 M
Slightly volatile
Property Plant And Equipment Net1.1 M1.3 M686.8 K
Slightly volatile
Accounts Payable4.1 M3.9 M1.5 M
Slightly volatile
Cash76.4 M75.7 M48.7 M
Slightly volatile
Non Current Assets Total1.3 M1.7 M827.7 K
Slightly volatile
Non Currrent Assets Other180.9 K341 K115.7 K
Slightly volatile
Other Assets1.091.15151.6 K
Pretty Stable
Cash And Short Term Investments85 M75.7 M54.1 M
Slightly volatile
Net Receivables12.3 M11.7 M2.4 M
Slightly volatile
Common Stock Shares Outstanding24.8 M44.5 M19.2 M
Slightly volatile
Non Current Liabilities Total83.3 M79.3 M31.1 M
Slightly volatile
Capital Surpluse182.1 M343.8 M134.5 M
Slightly volatile
Other Current Assets2.4 M4.6 M1.6 M
Slightly volatile
Total Liabilities98.9 M94.2 M37.9 M
Slightly volatile
Property Plant And Equipment Gross847.8 K1.4 M541.9 K
Slightly volatile
Preferred Stock Total Equity50.1 M84.1 M51.7 M
Slightly volatile
Total Current Assets92.1 M105.8 M58.6 M
Slightly volatile
Common Stock2.9 K5 K2.1 K
Slightly volatile
Property Plant Equipment46.2 K48.6 K393.5 K
Very volatile
Deferred Long Term Liabilities9.1 M8.6 M3.1 M
Slightly volatile
Non Current Liabilities Other147.7 K203.6 K91.7 K
Slightly volatile
Short and Long Term Debt Total29 M52.7 M20 M
Slightly volatile
Current Deferred Revenue62.4 K65.7 K2.5 M
Slightly volatile
Long Term Debt53.9 M51.4 M19 M
Slightly volatile
Common Stock Total Equity2.8 K3.5 K2.4 K
Slightly volatile
Long Term Debt Total44.4 M42.3 M17.7 M
Slightly volatile
Capital Lease Obligations977.2 K1.3 M1.5 M
Slightly volatile
Net Invested Capital69.9 M64.7 M98.6 M
Slightly volatile
Short and Long Term Debt11.8 M11.3 M3.9 M
Slightly volatile
Net Working Capital71.9 M91 M99.7 M
Slightly volatile
Short Term Debt454.1 K478 K1.6 M
Pretty Stable
Capital Stock3.5 K5 K2.6 K
Slightly volatile

Scpharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization140.6 K148 K194.5 K
Slightly volatile
Interest Expense3.8 M7.6 M2.5 M
Slightly volatile
Selling General Administrative81.5 M77.6 M19.2 M
Slightly volatile
Other Operating Expenses106.2 M101.1 M33.6 M
Slightly volatile
Research Development16.4 M12.1 M12.9 M
Slightly volatile
Cost Of Revenue11.9 M11.4 M1.8 M
Slightly volatile
Total Operating Expenses94.2 M89.7 M31.9 M
Slightly volatile
Interest Income3.6 M3.4 M1.1 M
Slightly volatile
Reconciled Depreciation19 K20 K173.9 K
Slightly volatile
Non Operating Income Net Other3.2 M3 M1.8 M
Slightly volatile

Scpharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.7 M5.4 M1.9 M
Slightly volatile
Begin Period Cash Flow64.8 M46.8 M41.9 M
Slightly volatile
Depreciation19 K20 K178.9 K
Slightly volatile
Capital Expenditures27 K21 K28.1 K
Very volatile
End Period Cash Flow72.8 M75.7 M46.4 M
Slightly volatile
Dividends Paid57.8 K62.1 K52.5 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.124.337816.0731
Slightly volatile
Days Sales Outstanding131118121
Slightly volatile
Stock Based Compensation To Revenue0.280.14980.3394
Slightly volatile
Capex To Depreciation1.321.051.9389
Slightly volatile
EV To Sales3.523.705815.5748
Slightly volatile
Inventory Turnover0.860.81720.2533
Slightly volatile
Days Of Inventory On Hand4244475.1 K
Slightly volatile
Payables Turnover3.072.92580.5831
Slightly volatile
Sales General And Administrative To Revenue3.143.533.8523
Slightly volatile
Research And Ddevelopement To Revenue0.660.3330.8222
Slightly volatile
Capex To Revenue5.0E-46.0E-40.0026
Slightly volatile
Cash Per Share1.611.69944.429
Very volatile
Days Payables Outstanding1191252.1 K
Slightly volatile
Income Quality0.730.82840.8996
Very volatile
Net Debt To EBITDA0.280.29661.1729
Pretty Stable
Current Ratio12.147.11547.9436
Slightly volatile
Receivables Turnover2.453.09972.9964
Slightly volatile
Capex Per Share4.0E-45.0E-40.005
Very volatile
Revenue Per Share0.460.81610.3886
Slightly volatile
Interest Debt Per Share1.51.35361.0782
Slightly volatile
Debt To Assets0.510.49010.2039
Slightly volatile
Operating Cycle5365645.1 K
Slightly volatile
Days Of Payables Outstanding1191252.1 K
Slightly volatile
Ebt Per Ebit0.861.31451.0335
Pretty Stable
Quick Ratio11.856.18087.7357
Slightly volatile
Net Income Per E B T1.161.171.0595
Slightly volatile
Cash Ratio4.835.08576.5388
Slightly volatile
Days Of Inventory Outstanding4244475.1 K
Slightly volatile
Days Of Sales Outstanding131118121
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00031.0077
Slightly volatile
Fixed Asset Turnover14.6627.337810.7769
Slightly volatile
Debt Ratio0.510.49010.2039
Slightly volatile
Price Sales Ratio4.124.337816.0731
Slightly volatile
Asset Turnover0.190.33790.1589
Slightly volatile
Gross Profit Margin0.770.68730.7208
Pretty Stable

Scpharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap111.7 M157.6 M143.6 M
Very volatile

Scpharmaceuticals Fundamental Market Drivers

Cash And Short Term Investments75.7 M

Scpharmaceuticals Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Scpharmaceuticals Financial Statements

Investors use fundamental indicators, such as Scpharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Scpharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue65.7 K62.4 K
Total Revenue36.3 M38.1 M
Cost Of Revenue11.4 M11.9 M
Stock Based Compensation To Revenue 0.15  0.28 
Sales General And Administrative To Revenue 3.53  3.14 
Research And Ddevelopement To Revenue 0.33  0.66 
Revenue Per Share 0.82  0.46 
Ebit Per Revenue(1.78)(1.87)

Currently Active Assets on Macroaxis

USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option
BCATBlackRock Capital Allocation
PDIPimco Dynamic Income
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:
How To Invest In Scpharmaceuticals
Details
Is Scpharmaceuticals Stock a good investment?
Details
What is Scpharmaceuticals' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Scpharmaceuticals Correlation against competitors.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.92)
Revenue Per Share
0.871
Quarterly Revenue Growth
0.926
Return On Assets
(0.49)
Return On Equity
(9.34)
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY